NUMI Stock Overview
Provides psychedelic-assisted psychotherapy products and services in Canada and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Numinus Wellness Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.03 |
| 52 Week High | CA$0.24 |
| 52 Week Low | CA$0.03 |
| Beta | 1.58 |
| 11 Month Change | -33.33% |
| 3 Month Change | -57.14% |
| 1 Year Change | -83.78% |
| 33 Year Change | -96.51% |
| 5 Year Change | n/a |
| Change since IPO | -97.09% |
Recent News & Updates
Recent updates
Not Many Are Piling Into Numinus Wellness Inc. (TSE:NUMI) Stock Yet As It Plummets 33%
Aug 24
It's Down 33% But Numinus Wellness Inc. (TSE:NUMI) Could Be Riskier Than It Looks
Jun 08Market Cool On Numinus Wellness Inc.'s (TSE:NUMI) Revenues Pushing Shares 30% Lower
Apr 17Slammed 27% Numinus Wellness Inc. (TSE:NUMI) Screens Well Here But There Might Be A Catch
Feb 25After Leaping 30% Numinus Wellness Inc. (TSE:NUMI) Shares Are Not Flying Under The Radar
Jan 05Numinus Wellness Inc.'s (TSE:NUMI) Popularity With Investors Is Clear
Apr 17Shareholder Returns
| NUMI | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | -14.3% | -6.1% | 0.9% |
| 1Y | -83.8% | 37.6% | 15.9% |
Return vs Industry: NUMI underperformed the Canadian Pharmaceuticals industry which returned 37.6% over the past year.
Return vs Market: NUMI underperformed the Canadian Market which returned 14.9% over the past year.
Price Volatility
| NUMI volatility | |
|---|---|
| NUMI Average Weekly Movement | 20.8% |
| Pharmaceuticals Industry Average Movement | 10.3% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in CA Market | 16.6% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: NUMI's share price has been volatile over the past 3 months.
Volatility Over Time: NUMI's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1964 | n/a | Payton Nyquvest | www.numinus.com |
Numinus Wellness Inc. provides psychedelic-assisted psychotherapy products and services in Canada and the United States. The company operates through Clinical Research Operations, Canadian Clinic Network, and U.S Clinic Network segments. The Clinical Research Operations segment offers clinical research management services to academic institutions and biotechnology companies.
Numinus Wellness Inc. Fundamentals Summary
| NUMI fundamental statistics | |
|---|---|
| Market cap | CA$11.22m |
| Earnings (TTM) | -CA$25.51m |
| Revenue (TTM) | CA$22.48m |
0.4x
P/S Ratio-0.4x
P/E RatioIs NUMI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NUMI income statement (TTM) | |
|---|---|
| Revenue | CA$22.48m |
| Cost of Revenue | CA$15.68m |
| Gross Profit | CA$6.80m |
| Other Expenses | CA$32.31m |
| Earnings | -CA$25.51m |
Last Reported Earnings
May 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.08 |
| Gross Margin | 30.27% |
| Net Profit Margin | -113.45% |
| Debt/Equity Ratio | 35.4% |
How did NUMI perform over the long term?
See historical performance and comparison